Modality
Peptide
MOA
BETi
Target
FcRn
Pathway
Lipid Met
Huntington'sMSBreast Ca
Development Pipeline
Preclinical
~May 2019
→ ~Aug 2020
Phase 1
Nov 2020
→ May 2030
Phase 1Current
NCT07649093
560 pts·Breast Ca
2020-11→2030-05·Not yet recruiting
560 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-05-254.2y awayInterim· Breast Ca
Trial Timeline
Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3
P1
Not yet…
Catalysts
Interim
2030-05-25 · 4.2y away
Breast Ca
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07649093 | Phase 1 | Breast Ca | Not yet recr... | 560 | EFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-179 | Johnson & Johnson | Approved | KRASG12C | |
| Cevizanubrutinib | Johnson & Johnson | Preclinical | FcRn | |
| LLY-1592 | Eli Lilly | NDA/BLA | FGFR | |
| Gelinaritide | AbbVie | Preclinical | FcRn | |
| Sovarapivir | AbbVie | Phase 2/3 | IL-13 | |
| BAY-8733 | Bayer | Preclinical | AuroraA | |
| Talalemzoparlimab | Gilead Sciences | Phase 1 | FcRn | |
| Sovafutibatinib | Moderna | Approved | FcRn | |
| BII-1564 | Biogen | Phase 2 | PSMA | |
| Sovanaritide | Argenx | Phase 3 | TNFα |